Anji Si releases earnings brief, reporting that in 2025 the company achieved a total revenue of 597 million yuan, a decrease of 6.19% year-on-year; net profit was 223 million yuan, down 24.06% year-on-year. During the reporting period, the medical device industry in which the company operates was affected by industry factors such as centralized volume-based procurement for domestic medical insurance and overseas tariff policies. The company’s main business in the minimally invasive endoscopic diagnosis and treatment field faced increased industry competition, leading to a temporary pressure on the company’s performance for the full year of 2025.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Anji Si: Net profit of 223 million yuan in 2025, down 24.06% year-on-year
Anji Si releases earnings brief, reporting that in 2025 the company achieved a total revenue of 597 million yuan, a decrease of 6.19% year-on-year; net profit was 223 million yuan, down 24.06% year-on-year. During the reporting period, the medical device industry in which the company operates was affected by industry factors such as centralized volume-based procurement for domestic medical insurance and overseas tariff policies. The company’s main business in the minimally invasive endoscopic diagnosis and treatment field faced increased industry competition, leading to a temporary pressure on the company’s performance for the full year of 2025.